Takeda Pharma considering expansion in Russia and other BRIC countries

Amid the falling dynamics in the European Union and the USA, Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) is considering a big expansion into the Russian pharmaceutical market, along with other BRIC (Brazil, Russia, India and China) markets, in the coming years.

According to Yasutika Hasegawa, president and chief of Takeda, in the case of Russia the company plans to start production of the three most important drugs for the Russian market at its recently commissioned plant in Yaroslavl (The Pharma Letter September 11).

Among the drugs which will be produced in Russia, are Actovegin (for the treatment of cerebral vascular disorders and stroke) Calcium-D3 (for the prevention and treatment of osteoporosis) and cardiomagnyl (for the prevention of cardiovascular disease). All of these drugs were previously part of portfolio of Nycomed, the Swiss company which was recently acquired by Takeda (TPL May 19, 2011). In the future, the company will consider the possibility of expanding the Russian capacities, depending on market conditions.